In an interview with Bloomberg Law, Keith Pagnani and Matt Hurd, Co-Heads of the Firm’s Healthcare and Life Sciences Practice, discussed S&C’s top ranking for healthcare deals announced in 2023 and their outlooks for the coming year. The Firm advised on $55.7 billion of global healthcare deals, which included advising Seagen in its $43 billion acquisition by Pfizer Inc., UnitedHealth Group Inc. in its $3.7 billion pending acquisition of Amedisys Inc., and Baxter International Inc. in its $4.3 billion sale of its Biopharma Solutions Division to a consortium led by Warburg Pincus. In addition, S&C helped Amgen close its $27.8 billion acquisition of Horizon Therapeutics, which was the largest healthcare deal announced in 2022 and the largest deal in Amgen’s history.
Keith said he expects increased deal volume for 2024, adding that “the biggest obstacle for companies wanting to do deals will be regulatory.”
“This year the regulators asked some good questions about deals and got some very strong answers from industry,” said Matt, who is “optimistic for another good year in 2024.”
Read: “Sullivan & Cromwell Tops Firms With $56 Billion in Health Deals.”